RXRX CIK: 1601830

Recursion Pharmaceuticals, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
10.2
FY22:
−8.43
FY23:
1.99
FY24:
13.6
FY25:
3.73
(positive)
Change from FY21 to FY25
millions USD
FY21:
−183
FY22:
−246
FY23:
−350
FY24:
−479
FY25:
−648
(positive)
Change from FY21 to FY25
millions USD
FY21:
−186
FY22:
−239
FY23:
−332
FY24:
−465
FY25:
−645
(positive)
Change from FY21 to FY25
millions USD
FY21:
−186
FY22:
−239
FY23:
−328
FY24:
−464
FY25:
−645

All amounts in millions USD Data source:SEC EDGAR